Transition Agreements in the Biotechnology Industry
122 Contracts & Agreements
- 2seventy bio, Inc. (2 contracts)
- AbbVie Inc. (2)
- ACADIA PHARMACEUTICALS INC (1)
- ADMA BIOLOGICS, INC. (2)
- Alector, Inc. (1)
- Alkermes plc. (2)
- Allena Pharmaceuticals, Inc. (2)
- Alliqua BioMedical, Inc. (2)
- Allogene Therapeutics, Inc. (1)
- Allovir, Inc. (1)
- Altimmune, Inc. (1)
- Aptevo Therapeutics Inc. (3)
- Arcellx, Inc. (1)
- Arcutis Biotherapeutics, Inc. (1)
- Athenex, Inc. (1)
- Aura Biosciences, Inc. (2)
- BioAtla, Inc. (1)
- Biogen Inc. (1)
- BIOMARIN PHARMACEUTICAL INC (4)
- Biostage, Inc. (2)
- BIOTIME INC (2)
- bluebird bio, Inc. (3)
- CANCER GENETICS, INC (1)
- CATALYST BIOSCIENCES, INC. (2)
- CATALYST PHARMACEUTICALS, INC. (2)
- Celsion CORP (1)
- Constellation Alpha Capital Corp. (1)
- CONTRAFECT Corp (1)
- Cyclerion Therapeutics, Inc. (2)
- CytoDyn Inc. (1)
- CytomX Therapeutics, Inc. (1)
- Deciphera Pharmaceuticals, Inc. (2)
- Dermira, Inc. (1)
- Dicerna Pharmaceuticals Inc (2)
- EXACT SCIENCES CORP (1)
- FIBROGEN INC (1)
- Gain Therapeutics, Inc. (1)
- GERON CORP (2)
- GLYCOMIMETICS INC (1)
- Gossamer Bio, Inc. (1)
- Grail, Inc. (1)
- GTX INC (1)
- iBio, Inc. (1)
- IMMUNOMEDICS INC (1)
- Karyopharm Therapeutics Inc. (3)
- Mirum Pharmaceuticals, Inc. (1)
- Moderna, Inc. (1)
- NEWLINK GENETICS CORP (1)
- NTN BUZZTIME INC (1)
- Nuo Therapeutics, Inc. (2)
- OncoCyte Corp (1)
- OPGEN INC (1)
- PDL BIOPHARMA, INC. (2)
- Pfenex Inc. (2)
- Praxis Precision Medicines, Inc. (1)
- Progenics Pharmaceuticals, Inc. (2)
- PUMA BIOTECHNOLOGY, INC. (1)
- Radius Health, Inc. (2)
- Retrophin, Inc. (1)
- RIGEL PHARMACEUTICALS INC (1)
- Sana Biotechnology, Inc. (1)
- SELECTA BIOSCIENCES INC (3)
- Sierra Oncology, Inc. (1)
- SOLENO THERAPEUTICS INC (1)
- Spring Bank Pharmaceuticals, Inc. (1)
- SQZ Biotechnologies Co (4)
- SUNESIS PHARMACEUTICALS INC (2)
- Surface Oncology, Inc. (1)
- Talaris Therapeutics, Inc. (1)
- Tonix Pharmaceuticals Holding Corp. (1)
- Ultragenyx Pharmaceutical Inc. (3)
- Vaxart, Inc. (1)
- Vericel Corp (5)
- VICAL INC (2)
- Viela Bio, Inc. (1)
- Vigil Neuroscience, Inc. (1)
- VITAL THERAPIES INC (1)
- XBiotech Inc. (2)
- Xenetic Biosciences, Inc. (1)
- Transition Services Agreement, dated as of November 13, 2023, by and between Mural Oncology, Inc. and Alkermes, Inc (Alkermes plc., Filed With SEC on November 15, 2023)
- Transition Services Agreement, dated as of November 13, 2023, by and between Alkermes, Inc. and Mural Oncology, Inc (Alkermes plc., Filed With SEC on November 15, 2023)
- Transition and Release Agreement, dated November 6, 2023, by and between Cadmus Rich and the Registrant (Aura Biosciences, Inc., Filed With SEC on November 9, 2023)
- Transition and Release Agreement, dated September 28, 2023, by and between Cadmus Rich and the Registrant (Aura Biosciences, Inc., Filed With SEC on November 9, 2023)
- Transition Agreement between the Registrant and Marshelle Smith Warren, dated October 3, 2023 (SQZ Biotechnologies Co, Filed With SEC on November 8, 2023)
- Transition Agreement between the Registrant and Lawrence Knopf, dated October 3, 2023 (SQZ Biotechnologies Co, Filed With SEC on November 8, 2023)
- Transition Agreement between the Registrant and Richard Capasso, dated October 3, 2023 (SQZ Biotechnologies Co, Filed With SEC on November 8, 2023)
- Transition Agreement between the Registrant and Howard Bernstein, dated October 3, 2023 (SQZ Biotechnologies Co, Filed With SEC on November 8, 2023)
- Transition Agreement effective as of August 22, 2023 by and between CytomX Therapeutics, Inc., and AbbVie Global Enterprises Ltd (CytomX Therapeutics, Inc., Filed With SEC on November 7, 2023)
- Transition Agreement b (Deciphera Pharmaceuticals, Inc., Filed With SEC on October 30, 2023)
- Amendment to Transition Services Agreement between Eisai Inc., a subsidiary of Eisai and the Company, dated as of July 31, 2023 (certain identified information has been excluded... (CATALYST PHARMACEUTICALS, INC., Filed With SEC on August 9, 2023)
- Amendments 1, 2 and 3 to License and Transition Services Agreement with Forma Therapeutics, Inc (RIGEL PHARMACEUTICALS INC, Filed With SEC on August 1, 2023)
- TRANSITION SERVICES AGREEMENT (Tonix Pharmaceuticals Holding Corp., Filed With SEC on July 3, 2023)
- Transition Agreement and Release by and between the Company and Sunil Agarwal, dated as of April 28, 2023 (Sana Biotechnology, Inc., Filed With SEC on May 8, 2023)
- Transition Agreement, by and between the Company and John Dobak, dated March 1, 2023 (Constellation Alpha Capital Corp., Filed With SEC on May 4, 2023)
- Transition Agreement dated February 21, 2023, by and between the Company and John Magnani, Ph.D (GLYCOMIMETICS INC, Filed With SEC on May 3, 2023)
- Transition and Release Agreement, by and between Fresh Tracks Therapeutics, Inc. and Robert B. Brown, dated as of February 1, 2023 (VICAL INC, Filed With SEC on February 7, 2023)
- Form of Transition Services Agreement between Eisai, Inc., a subsidiary of Eisai, and the Company (certain identified information has been excluded from the exhibit because it... (CATALYST PHARMACEUTICALS, INC., Filed With SEC on December 22, 2022)
- Transition Agreement, by and between the Registrant and Suzanne T. Ildstad, dated August 13, 2022 (Talaris Therapeutics, Inc., Filed With SEC on November 10, 2022)
- Transition Agreement, by and between the Company and Eric Richman, dated September 19, 2022 (Gain Therapeutics, Inc., Filed With SEC on September 20, 2022)
- Transition Agreement and Release, dated as of August 14, 2022, by and between Cara Cassino, M.D. and ContraFect Corporation (CONTRAFECT Corp, Filed With SEC on August 16, 2022)
- Amendment to the Transition Services Agreement, by and between 2seventy bio, Inc. and the Registrant (bluebird bio, Inc., Filed With SEC on August 4, 2022)
- Transition Agreement dated July 26, 2022, by and between Praxis Precision Medicines, Inc. and Bernard Ravina (Praxis Precision Medicines, Inc., Filed With SEC on July 26, 2022)
- Transition Services Agreement, dated as of (VICAL INC, Filed With SEC on May 3, 2022)
- Transition Agreement, dated March 28, 2022, between the Company and Sharon Shacham (Karyopharm Therapeutics Inc., Filed With SEC on March 29, 2022)
- Transition Agreement, dated March 28, 2022, between the Company and Michael G. Kauffman (Karyopharm Therapeutics Inc., Filed With SEC on March 29, 2022)
- Transition Agreement and Release dated March 22, 2022 between the Company and Mark Kowalski (Sierra Oncology, Inc., Filed With SEC on March 23, 2022)
- Transition Agreement and Release between the Registrant and David Hilbert, Ph.D., dated January 7, 2022 (Arcellx, Inc., Filed With SEC on January 14, 2022)
- Transition Agreement, by and between the Registrant and Richard A. Fisher, dated November 17, 2021 (Vigil Neuroscience, Inc., Filed With SEC on November 19, 2021)
- Amendment to Executive Transition Services Agreement (Aptevo Therapeutics Inc., Filed With SEC on November 12, 2021)
- Executive Transition Services Agreement (Aptevo Therapeutics Inc., Filed With SEC on November 12, 2021)
- Transition Agreement by and between FibroGen, Inc. and Pat Cotroneo, dated as of August 14, 2021 (FIBROGEN INC, Filed With SEC on November 9, 2021)
- Transition Services Agreement, dated as of November 3, 2021, by and between 2seventy bio, Inc. and bluebird bio, Inc (2seventy bio, Inc., Filed With SEC on November 4, 2021)
- Transition Services Agreement, dated as of November 3, 2021, by and between bluebird bio, Inc. and 2seventy bio, Inc (2seventy bio, Inc., Filed With SEC on November 4, 2021)
- Transition Services Agreement, dated as of November 3, 2021, by and between 2seventy bio, Inc. and bluebird bio, Inc (bluebird bio, Inc., Filed With SEC on November 4, 2021)
- Transition Services Agreement, dated as of November 3, 2021, by and between bluebird bio, Inc. and 2seventy bio, Inc (bluebird bio, Inc., Filed With SEC on November 4, 2021)
- Transition Agreement dated October (Retrophin, Inc., Filed With SEC on October 12, 2021)
- Transition Agreement, dated September 7, 2021, by and between Shehnaaz Suliman and Alector, LLC (Alector, Inc., Filed With SEC on September 7, 2021)
- Transition Agreement by and between AlloVir, Inc. and David Hallal, dated May 18, 2021 (Allovir, Inc., Filed With SEC on August 6, 2021)
- Transition Agreement by and between BioAtla, Inc. and Carolyn Anderson Short, dated March 23, 2021 (BioAtla, Inc., Filed With SEC on May 12, 2021)
